The Effect of Arvanil on Prostate Cancer Cells Studied by Whole Cell High Resolution Magic Angle Spinning NMR

Wei Li* and Bob M Moore II*
Department of Pharmaceutical Sciences, College of Pharmacy, The University of Tennessee Health Science Center, Memphis, TN 38163, USA

Abstract
The transient receptor potential cation channel subfamily V member 1 (TRPV1) has recently gained attention as a potential target for the development of novel antineoplastic agents. It has been reported that the TRPV1 agonist arvanil has effective antiproliferative effects in studies using human breast cancer cell lines. In an extension of this research we have evaluated the IC₅₀ values of arvanil in the prostate cancer cell lines PPC-1 (primary) and TSU (metastatic). Both TSU and PPC-1 cell lines are sensitive to treatment with arvanil. This result prompted our investigations into the changes in "cell metabolism" associated with prostate cancer progression and the effect of arvanil treatment. To this end, we have employed High Resolution Magic-Angle Spinning (HR-MAS) NMR spectroscopy on whole cells to determine the differences in the relative amount of cell metabolites and changes in small molecule metabolism following treatment of the TSU and PPC-1 cells with arvanil. We evaluated and confirmed that the existing "biomarkers" such as elevated ICho and decreased Cho in primary cancer are well correlated with prostate cancer progression. In addition, metastatic TSU cells also contain elevated level of lactate and glutamine, and contain much less creatine. Upon treatment with arvanil, a number of biomolecules were found to undergo changes in intracellular levels during apoptosis. These data will potentially permit the further characterization of signaling pathways associated with TRPV1 activation as well as identifying new targets for the development of novel antineoplastic agents.

Keywords: High resolution magic spinning NMR; TRPV1; Arvanil; Prostate cancer

Introduction
Prostate cancer is the second most common cancer in men, exceeded only by lung and bronchial cancer. Based on the Cancer Facts and Figures 2013 compiled by American Cancer Society, an estimated 238,590 new cases of prostate cancer will be diagnosed in the United States and approximately 29,720 men will die of this disease. Accurate and timely diagnosis of prostate cancer is the key to control disease progression and effective early treatment, as up to 70% of patients are already in the advanced-stage of disease when initially seen.

It has been well recognized that with the tissue malignancy, there are detectable biochemistry changes. These changes can be observed in the metabolite profiles by NMR or MS and metabolite biomarkers can be identified [1-7]. High-Resolution Magic Angle Spinning (HRMAS) NMR has been used to study prostate cancer tissues and cells with much successfulness since its introduction in the late 1990s [8-12]. By spinning the sample at the "magic-angle", the dipolar couplings, chemical shift anisotropy and magnetic susceptibility changes are effectively reduced, and liquid-like spectra can be obtained in tissues and cultured cells. Tissues and cells can be well preserved during and after the HRMAS NMR experiments [10,13-16].

The Transient Receptor Potential cation channel subfamily V member 1 (TRPV1) has recently gained attention as a potential target for the development of novel antineoplastic agents [17-20]. It has been reported that the TRPV1 agonists have effective antiproliferative effects in studies using human breast cancer cells lines. In an extension of this research we have evaluated the IC₅₀ values of arvanil, a TRPV1 agonist, in the prostate cancer cell lines PPC-1 (primary) and TSU (metastatic). We also employed High Resolution Magic-Angle Spinning (HR-MAS) NMR spectroscopy on whole cells to determine the differences in the relative amount of cell metabolites and changes in small molecule metabolism following treatment of the TSU and PPC-1 cells with arvanil.

Materials and Methods
Cell culture and bioassay of arvanil on prostate cancer cell lines
PPC-1 cells were purchased from American Type Cell Culture and TSU cells were a gift from Dr. James Dalton, GTx Inc. Memphis, TN. Cells were seeded in 96-well polystyrene flat-bottom plates (7,500 cells/well) at 70–80% confluency in a 100 µl total volume of complete growth media (FK12K medium containing 10% fetal bovine serum) and incubated overnight at 37°C in an atmosphere of 5% CO₂ and 95% air to allow for adherence. The media were then replaced with serum-free media and the cultures were treated with escalating amounts of arvanil and cell death was analyzed at 18 h, using the BioTek Synergy 2 Multidetection Microplate Reader (BioTek Instruments, Inc.). The percentage of viable cells present in the culture at each time point was calculated by comparing the absorbance value at 450 nm from the CCK-8 assay (Dojindo Molecular Technologies) for each condition with untreated control cells. All assays were conducted per manufacturer's protocol. All described values represent the average of three data points per determination and three independent determinations.

NMR sample preparation
Cells were harvested when cells are at 70~80% confluence using Trypsin digestion. After washed with D₂O/PBS for three times, the suspended cells were placed in a NMR nanotube (a total volume of 40 µl) for HRMAS NMR measurements. In the study of arvanil treatment for prostate cancer cells, a concentration of 20 µM of arvanil was used in the cell culture for various time periods before the cells were prepared for NMR measurement.

HRMAS NMR measurement
All HRMAS experiments were performed at 37°C on an Agilent...
Results and Discussion

Arvanil treatment potently suppresses prostate cancer cell proliferation

To select a working concentration of arvanil for our HRMAS studies the IC\textsubscript{50} was determined in the primary cancer cell line PPC-1 and a metastatic cell line TSU (Figure 1). Both PPC-1 (IC\textsubscript{50} 11.8 µM) and TSU (IC\textsubscript{50} 7.68 µM) cell viability was significantly reduced by increasing concentrations of arvanil. An IC\textsubscript{50} of ~20 µM was selected for the studies to maximize cellular responses in an effort to enhance the detection of specific metabolites associated with arvanil treatment. Thus, this study compared the metabolic profiles of primary and metastatic prostate cancer cells to evaluate biomarkers in prostate cancer prognosis (Figure 1).

Primary PPC1 and metastatic TSU prostate cancer cells have different metabolic profiles revealed by HRMAS NMR

Before evaluating the effects of arvanil treatments on metabolite changes in prostate cancer cells, we first compared the basal level metabolic profiles for the two prostate cancer cell lines tested. The metabolic profiles of the two prostate cancer cells were measured using HRMAS NMR. PPC1 cells represent primary prostate cancer stage and TSU cells represent metastatic prostate cancer stage. Figure 2 shows the HRMAS \textsuperscript{1}H NMR spectra of the two prostate cancer cell lines. These metabolite profiles are well comparable to that obtained from HRMAS measured on tissues directly with slightly higher resolution. This is expected because cultured prostate cancer cells are more homogeneous compared with whole tissues directly from patients (Figure 2).

Compared with primary prostate cancer PPC1 cells, the metastatic TSU cells contain significantly elevated levels of lactate (1.33 ppm), choline (3.20 ppm), glutamate (2.36 ppm) and reduced level of creatine (3.05 ppm and 3.85 ppm). The three choline metabolites (free choline, phosphocholine and glycerol phosphocholine) are clearly resolved in the both of the spectra, and the total amount of choline (tCho), which includes these three metabolites, are significantly higher in the metastatic TSU cells than that in primary PPC1 cells. There is no detectable citrate in either of the prostate cancer lines.

Elevated tCho and decreased amount of creatine have been consistently observed in literature reports, and the ratio of tCho/creatin has been suggested as a biomarker in prostate cancer diagnosis. Increased amount of tCho in both PPC1 and TSU cells is likely due to accelerated membrane synthesis of rapidly dividing cancer cells, although altered phosphorous metabolism in cancer cells may also be responsible. The larger amount of tCho in TSU compared with that in primary PPC1 cells indicates that tCho is directly related to prostate cancer cell malignancy as well as its metastatic progress. Citrate, which is abundant in normal prostate tissues and cells, is below the detection level in both of the prostate cancer cell lines, consistent with literature reports [27,28].

Effect of arvanil treatment on the prostate cancer cell lines

When treated with arvanil for different time periods, changes...
in metabolic profiles in the choline regions were observed for both PPC1 and TSU cell lines. Figures 3 and 4 show the metabolite profiles following treatment with arvanil in PPC1 and TSU cells, respectively.

There was a consistent trend of metabolite changes up to 150 minutes of arvanil treatment. At 270 minutes, a substantial amount of cells has been found dead under a microscope, and after washing, the amount of cells that contribute to the NMR signal drops significantly. Compared with vehicle controls, the absolute amount of choline increases for both PPC1 and TSU cells, as shown in Figure 5. The relative amount of choline expressed as a ratio to the total choline also increased upon arvanil treatment (Figure 5).

The mechanism whereby metabolism of choline, PC, and GPC in prostate cancer is affected by treatment with TRPV1 remains to be determined. It has been reported that capsaicin, a TRPV1 agonist, induces apoptosis in PC-3 cells and inhibits tumor growth in vivo. The mechanism of the effects was reported to involve reactive oxygen species, mitochondrial depolarization followed by caspase-3 mediated apoptosis [25]. Although we have not examined mitochondrial function in our studies, the time dependent changes in choline, PC, and GPC are consistent with mitochondria dysfunction. Specifically, increased Cho metabolism has been demonstrated in diseases manifesting mitochondrial dysfunction [29,30] and has been used as a biomarker for this impairment [31]. The differences in the PPC1 and TSU Cho profiles may reflect induction of choline kinase which has been reported in metastatic cancer cells [32]. Thus, HRMAS has demonstrated not only the ability to detect potential biomarkers, as noted above, but also provides a potential window into the metabolic vents associated with anti-cancer drug activity.

**Conclusion**

Our HR-MAS analyses on whole cells confirmed that several existing biomarkers (e.g. increased tCho and decreased citrate) correlate well with stages of prostate cancer progression. Compared with early stage prostate cancer cells (PPC1 cells), metastatic prostate cancer cells (TSU cells) also contain much less creatine but contain higher level of lactate and glutamine, consistent with the observations that more aggressive cancer cells are generally more dependent on aerobic glycolysis for their proliferation [33]. When prostate cancer cells were treated with arvanil, several molecules were found to undergo changes in intracellular levels during apoptosis. Collectively, these data provide...
rationale to characterize signaling pathways associated with TRPV1 activation and to identify new potential targets for the development of novel antineoplastic agents.

Acknowledgement

The work is supported by funds from College of Pharmacy, the University of Tennessee Health Science Center.

References